


 VIDO
2025-26
ANNUAL
REPORT

 **FROM**
 **RESEARCH**
 **TO READINESS**



FROM RESEARCH TO READINESS

Emerging infectious diseases continue to challenge human and animal health and affect communities around the world.

Preparing for these challenges is at the heart of VIDO's work. As Canada's Centre for Pandemic Research, VIDO brings together leading scientific experts, advanced infrastructure, and a collaborative approach to develop solutions that help ensure Canada's readiness to protect public health, animal health, and food security.

Through innovative research and development, training, and global partnerships, VIDO is building a more resilient future while ensuring Canada has specialized capacity ready to support scientists, partners, and communities when emerging biological threats arise.



TABLE OF CONTENTS

VIDO Team	2
Mission, Vision, and Values	3
Message from the Chair	4
Board of Directors	5
Message from the Director and CEO	6
Senior Leadership Team	7
Community Liaison Committee Report	8
10-Year Transformation Roadmap	9
Canada's Centre for Pandemic Research	10
People and Culture	11
Organizational Excellence	12-17
World Leading Containment Facilities and Capacity	18-19
Global Partnerships	20
Funding	21
Friends of VIDO	22-23
2025-26 Contributors	24

VIDO TEAM



**A GLOBAL TEAM UNITED FROM OVER
32 COUNTRIES, DRIVING INNOVATION
IN INFECTIOUS DISEASE RESEARCH
AND VACCINE DEVELOPMENT**

VISION

Healthy people, healthy animals

MISSION

To protect the world from infectious diseases

VALUES

Excellence

We bring relentless passion for progress and meaningful impact every day, as we strive to be known as global thought leaders and innovators.

Commitment

We are purpose-driven, committed to being the best we can be, constantly working to improve ourselves, to cultivate our knowledge and attitudes and to achieve positive change.

Respect

We strive for inclusivity and exhibit deferential regard for all manners of diversity and value the talents and beliefs of our clients, partners, and colleagues.

Team

We understand that success lies in our ability to trust each other, behaving with integrity through constructive collaboration, we support one another in the achievement of a common vision.

Accountability

We proactively focus on solutions and results by engaging others in decisions and plans that involve them, and collectively commit to those decisions.



MESSAGE FROM THE CHAIR

ADVANCING SCIENCE. STRENGTHENING PREPAREDNESS.

As VIDO enters its next chapter, this year's theme "From Research to Readiness" reflects both who we are and where we are going.

Over the past year, I have been struck by how VIDO continues to translate scientific excellence into real-world preparedness. The organization's strength lies not only in discovery, but in its ability to move knowledge forward into solutions, into partnerships, and ultimately into readiness for whatever challenges may emerge.

This readiness is built through collaboration. As a national science facility, VIDO not only advances its own research, but also makes specialized expertise, infrastructure, and training opportunities available to partners across Canada and around the world.

VIDO's growing network of partners, across governments, academia, and international organizations, reflects a shared commitment to strengthening global resilience. These relationships ensure that the science developed here in Canada contributes to broader efforts to protect people, animals, and food systems around the world.

As a Board, we are proud to support an organization that is both deeply rooted in scientific rigor and increasingly positioned as a trusted partner in times of uncertainty. That balance, between innovation and application, is what makes VIDO so impactful.

On behalf of the Board of Directors, I extend my sincere thanks to the VIDO team, its partners, and its supporters. Your continued dedication is what transforms research into readiness, and readiness into lasting impact.

Amy Cronin
Chair, Board of Directors

BOARD OF DIRECTORS



(in order left to right)

Volker Gerdts (CEO & Director) – Canada (SK)

Duane Thompson – Canada (SK)

Jeremy Gowler – United States

Amy Cronin – Canada (ON)

J. Mark Lievonen – Canada (ON)

Heather Davis – Canada (ON)

Not pictured: Francisco Diaz-Mitoma – Canada (ON), Kari Harvey – Canada (SK), Gillian Muir – Canada (SK),
Baljit Singh – Canada (SK), Preston Smith – Canada (PEI)



MESSAGE FROM THE DIRECTOR AND CEO

TURNING DISCOVERY INTO ACTION FOR A CHANGING WORLD

The pace and complexity of global health challenges continue to evolve. Around the world, outbreaks of high-consequence and emerging infectious diseases continue to test public health systems, disrupt communities, and remind us how quickly local events can become global concerns. Emerging diseases, shifting environmental conditions, and increased global connectivity all reinforce a simple reality: preparedness is no longer optional. It is essential.

At VIDO, our work increasingly reflects a deliberate shift, not away from discovery, but toward ensuring that discovery leads to action. We are focused on bridging the gap between early-stage research and deployable solutions that can be called upon when and where they are needed most.

This means strengthening our ability to develop and scale vaccines and therapeutics, advancing high containment research to better understand known and unknown pathogens, and expanding the use of large animal models to generate meaningful, translatable data. It also means working alongside a broader range of partners who share a common goal of improving readiness in the face of uncertainty.

In the past year, we have continued to build relationships that extend the reach and relevance of our science. As recent outbreaks around the world have shown, preparedness depends on coordinated networks that can detect, understand, and respond to infectious disease threats before they escalate.

These collaborations, spanning national and international agencies, are helping to ensure that VIDO's capabilities contribute not only to public health preparedness, but also to wider efforts aimed at safeguarding communities, supporting critical infrastructure, and strengthening

coordinated global responses. This includes supporting areas of growing national importance, such as biodefence and medical countermeasure development, where trusted science, secure infrastructure, and coordinated partnerships are essential.

Readiness is not built overnight. It requires sustained investment, trust, and the ability to anticipate what comes next. VIDO's vertically integrated model, from discovery through to development and manufacturing, positions us uniquely to respond with both speed and precision. It allows us to move vaccine candidates forward efficiently and to support partners at every stage of the process.

As Canada's Centre for Pandemic Research, VIDO is also committed to serving as a platform for others, providing access to specialized capabilities, supporting collaborative science, and helping train the next generation of researchers who will strengthen Canada's preparedness for decades to come.

I would like to thank our funders and supporters, including the Government of Canada, the Government of Saskatchewan, the City of Saskatoon, and the Friends of VIDO. Your continued support enables us to not only pursue scientific excellence, but to ensure that our work translates into meaningful readiness for the future.

The challenges ahead are complex, but so too are the opportunities. Together, we are building a more prepared, more resilient world.

Volker Gerdts
Director and CEO

SENIOR LEADERSHIP TEAM



Volker Gerdts
Director and CEO



Cam Ewart
Director of Facilities



Jordan Hamel
Director of Human Resources



Paul Hodgson
Director of Operations



Trina Racine
Director of Vaccine
Development



Jose Rodriguez
Director of Business
Development



Andrew Van Kessel
Director of Research



Lorne Vanin
Director of Finance

2025-2026 COMMUNITY LIAISON COMMITTEE REPORT



2025-2026 CLC members:

Simon Kapaj, Patricia Roe, Sarina Gersher (Chair), Dick Batten, Robin Chapman, Susan Lamb, Brian Gibbs, Volker Gerdts

Not pictured: Vance McNab, Doug Wegren, Tracey Thue (ex-officio), Stacy Strom (ex-officio), Jill Van Kessel (ex-officio), Heather Persson (ex-officio), and Kelly Richmond (ex-officio)

The Community Liaison Committee (CLC) is an example of the best practices for containment facilities worldwide. Comprised of community leaders, the committee's role is to provide oversight and information to the public regarding safety and security at VIDO. The committee helps create and maintain an atmosphere of trust, confidence, and transparency with the public.

The CLC was created by the University of Saskatchewan to independently serve to ensure full and open communication on safety issues related to VIDO's high containment operations.

In the 2025-2026 fiscal year the CLC received reports of 11 incidents. All incidents were resolved to the satisfaction of the committee with no risk to the public. These resolutions included additional training, equipment replacement and

procedure changes. We received regular reports on security and communications. In addition, we have completed both conflict of interest and confidentiality policies.

Drs. Yan Zhou, Antonio Facciuolo and Dr. Volker Gerdts made presentations at our community meeting, in May 2025. The committee follows current issues by regular briefings from VIDO scientists.

For up-to-date information, please visit our website at vidoclc.ca. In addition, community members can contact the CLC with any questions or concerns at vidoclc@usask.ca.

Sarina Gersher
Chair, Community Liaison Committee

TEN-YEAR TRANSFORMATION ROADMAP

VIDO has a vision for our future and a 10-year roadmap to help guide this transformation. This roadmap will help ensure our organization remains a global leader for emerging infectious diseases.

WE WILL FOCUS ON THE FOLLOWING PRIORITIES:

1.



PEOPLE AND CULTURE

Enhance leadership capabilities throughout VIDO that embrace inclusivity and promote an entrepreneurial team culture to ensure organizational viability.

2.



ORGANIZATIONAL EXCELLENCE

Deliver scientific excellence that consistently supplies products and services that meet stakeholder needs.

3.



INFRASTRUCTURE AND CAPACITY CREATION

Establish world-class research capacity that positions Canada as a leader in the response to global emerging diseases and pandemics.

4.



PARTNERSHIP DEVELOPMENT

Establish a robust business development model, and build global strategic partnerships to secure long-term value creation for stakeholders.

CANADA'S CENTRE FOR PANDEMIC RESEARCH



VIDO is one of the most advanced high containment infectious disease research centres in the world, designed to accelerate the development of vaccines and therapeutics that protect both human and animal health. With the upcoming ability to study any pathogen, including those requiring the highest level of containment, VIDO is helping Canada and the world prepare for future pandemics. The facility brings together everything needed to develop vaccines and treatments under one roof: from early discovery to testing the effectiveness of new medicines and the capacity to manufacture them in-house. By working with leading partners across Canada and around the globe, VIDO is creating faster, more coordinated responses to emerging threats.

READY FOR ANY PATHOGEN

VIDO's facilities include containment level 2 (CL2), and containment level 3 (CL3). VIDO is currently finalizing construction of its new containment level 4, enabling safe research on all pathogens from familiar viruses and bacteria to newly emerging/re-emerging threats affecting people and animals.

DESIGNED FOR FLEXIBILITY

Our multidisciplinary scientists and diverse facilities support research in a wide range of animals, from livestock and wildlife to insects, bats and exotic species, allowing more accurate disease models and faster progress toward real-world solutions for humans and animals. This flexibility supports the development of new vaccines, therapeutics and other medical countermeasures by helping demonstrate safety and efficacy when bringing new medicines to market.

FROM DISCOVERY TO DELIVERY

VIDO combines research, testing, and vaccine manufacturing together in one location. By integrating these capabilities, VIDO can accelerate the development of medical countermeasures including vaccines and therapeutics for both human and animal use.

BUILT FOR CANADA, CONNECTED TO THE WORLD

As a Canada Foundation for Innovation Major Research Facility, VIDO supports researchers, governments, industry, and partners worldwide with access to specialized containment, efficacy studies, vaccine development, and manufacturing expertise. A key part of Canada's Biomanufacturing and Life Sciences Strategy and Canada's new Defence Industrial Strategy, VIDO works with partners across Canada and globally to improve pandemic preparedness and response capacity against biological threats.

A PLATFORM FOR CANADIAN RESEARCH AND TRAINING

VIDO provides opportunities for students, trainees, visiting scientists, and collaborators to work in specialized research environments that are not widely available in Canada or globally. By supporting access, VIDO helps strengthen Canada's broader infectious disease research and innovation ecosystem.



CANADA'S LARGEST HIGH CONTAINMENT FACILITY

- Equivalent in size to 2.5 football fields
- Includes 15 CL3-Ag animal rooms and 7 CL3 laboratories
- Tested over 500 new COVID-19 medicines
- Being upgraded to Containment Level 4 (CL4) to study any pathogen



VACCINE DEVELOPMENT CENTRE

- CL3-capable vaccine production for both humans and animals
- GMP compliant
- Manufacturing capability for all vaccine platforms



NEW CL2 ANIMAL HOUSING

- Expanded capacity for exotic species including bats, ticks, non-human primates and bison
- Six times more animal housing capacity than original facility



MODERNIZING CL2 LABORATORIES

- Upgrading CL2 laboratories
- Established centralized core labs for microscopy and flow cytometry
- New centralized media and glassware preparation facilities

PEOPLE & CULTURE

VIDO's ability to move from research to real-world impact begins with its people.

Across the organization, VIDO's team brings the expertise and dedication needed to advance science that protects people, animals, and food security. As global health challenges grow more complex, building a strong, connected, and resilient workforce remains essential.

Trainees remain one of VIDO's most dynamic and important groups. Each year, students, interns, graduate trainees, and postdoctoral fellows from around the world develop specialized skills in infectious disease research, containment, animal models, vaccine development, and biomanufacturing. These opportunities help build the next generation of scientific leaders that Canada will need to respond to future health, agricultural, and biological threats. A recent study by Praxis Research found that **more than 40% of VIDO alumni remained in Saskatchewan**, while **80% continued working in Canada**, demonstrating VIDO's key role in developing and retaining highly qualified personnel.

VIDO also invests in professional development, leadership training, and initiatives that strengthen collaboration, inclusion, and workplace wellbeing. These efforts help ensure the organization is not only scientifically strong, but operationally ready.

Strategic hiring has further strengthened VIDO's capabilities, with new roles supporting vaccine development, regulatory quality, veterinary expertise, and project delivery.

As VIDO looks ahead, its ambitious vision will continue to be shaped by its most valuable asset: its people.

REPRESENTATION

FROM

32

COUNTRIES

OVER

218

STAFF AND
TRAINEES



ORGANIZATIONAL EXCELLENCE:

HUMAN AND ANIMAL HEALTH

VIDO's research is grounded in the connection between human and animal health. High-priority and emerging pathogens, including unknown threats like "Disease X," a term used to describe a future disease caused by a currently unknown pathogen, require strong scientific expertise, specialized containment infrastructure, and coordinated partnerships. Together, these capabilities support pandemic preparedness, biodefence, food security and the development of vaccines, therapeutics, and other tools that can be advanced when they are needed most.

As a national science facility, VIDO enables the advancement of internal and external scientific innovation through specialized expertise, containment capacity, vaccine development, and training.

The following research highlights reflect VIDO's role in advancing infectious disease preparedness in Canada and internationally. For more detailed information please visit vido.org/research/research-projects.php.



ADVANCING NOVEL TB VACCINE RESEARCH TO PROTECT LIVESTOCK AND PUBLIC HEALTH


VIDO researchers are developing a novel vaccine candidate for bovine tuberculosis (TB), a serious infectious disease that primarily affects cattle but can also infect wildlife, other livestock and people. Caused by *Mycobacterium bovis*, bovine TB can be difficult to detect and disruptive for producers, as detections may lead to extensive testing, quarantines, and difficult herd management decisions.

Canada maintains official bovine TB-free status, but the disease

is prevalent in many countries. Recent detections reinforce the need for better tools, including improved vaccines that can reduce bovine TB globally, while helping protect Canadian herds by lowering the risk of the disease being imported into Canada. A major challenge is that some vaccine approaches can interfere with routine diagnostic testing, falsely identifying an animal as positive for TB infection, which could lead to trade implications. An important feature of VIDO's vaccine is that

it is designed to Differentiate Infected from Vaccinated Animals (DIVA). As a result, VIDO's bovine TB vaccine would not impact the testing systems that are essential for disease surveillance and control.

By advancing this vaccine candidate, VIDO is helping strengthen animal health, reduce risks for producers, support food security, and contribute to broader efforts to protect both animals and people.



BUILDING LAB-GROWN LUNG MODELS TO ACCELERATE RESPIRATORY DISEASE RESEARCH


VIDO scientists are developing lab-grown lung organoids, or “mini lungs,” that mimic key features of human lungs. These 3D models give researchers a more realistic way to study how respiratory pathogens, including SARS-CoV-2 and Influenza A, infect the body and interact with different lung cells.

Because organoids are developed from donated human

tissue, they can help researchers study how genetic differences between people may affect their response to infection or treatment. Once generated, organoids can be preserved and used in future studies, creating a valuable resource for comparing results across different donors and diseases.

By using these advanced models, VIDO researchers can

identify which lung cells are most likely to be infected, learn how the cells respond, and test new medicines to determine if they should advance into later studies. This work is helping accelerate respiratory disease research, support new scientific modelling, and strengthen pandemic preparedness for future infectious disease threats.




USING HIGH PERFORMANCE COMPUTING TO ACCELERATE VACCINE DEVELOPMENT

VIDO is using powerful computing tools to better understand infectious diseases and develop new vaccines more quickly. New web-based platforms, including wiseFlu and PathwayDenester, developed by VIDO scientists are online with open access to help researchers analyze large datasets, track disease threats, and support vaccine design. Because these tools are freely available, they extend VIDO's impact beyond its physical infrastructure and support researchers around the world.

Through the University of Saskatchewan's QuanTA initiative, which includes the first quantum computer owned by a university in Canada, VIDO researchers are helping connect infectious disease research with emerging technologies that can accelerate vaccine and therapeutic development.

This work includes building advanced digital models of the immune system using artificial intelligence, machine learning, and quantum computing. These models can help researchers

better understand who may be more vulnerable to certain illnesses, how diseases progress, and how existing medicines could be used in new ways. The approach is also supporting a more advanced vaccine design pipeline by combining traditional computer-based methods with newer artificial intelligence tools to identify promising vaccine targets faster.



UNCOVERING SARS-COV-2'S HIDDEN WEAKNESSES TO INFORM FUTURE ANTIVIRAL STRATEGIES

A new collaboration with the University of British Columbia is studying how SARS-CoV-2, the virus that causes COVID-19, interacts with the body's early immune defences. The scientists found that while SARS-CoV-2 can interfere with one part of our 'antiviral warning system' and thereby promote infection, that same action may also unintentionally activate another protective response that helps slow infection.

This research suggests that some

strategies used by viruses to avoid detection by our immune system may come with trade-offs, creating opportunities that scientists can potentially target. Understanding how SARS-CoV-2 evades the body's defences, and where those defences still succeed, can help reveal new opportunities for antiviral treatments.

By uncovering these hidden vulnerabilities, researchers better understand coronavirus infections and identify weak


points that could inform future therapies. This work also strengthens pandemic preparedness by advancing knowledge that may be applied to other emerging viruses with similar immune-evasion strategies.

ENABLING DISCOVERY THROUGH COLLABORATION

As a national science facility, VIDO supports research led by partners across Canada and internationally by contributing

specialized expertise and infrastructure. These projects help expand access to unique research tools, strengthen

preparedness, and advance infectious disease solutions for both human and animal health.



BUILDING SHARED TOOLS FOR FASTER VACCINE RESEARCH

Through a partnership with Coalition for Epidemic Preparedness Innovations' (CEPI) Preclinical Model Network and Adjuvant Library Group, VIDO developed specialized scientific tools that will be made available to research networks around the world to help CEPI achieve their mission.

These tools included animal models, a pseudovirus library and adjuvant technologies. As part of this, VIDO also developed a humanized mouse model for MERS-CoV, a coronavirus with pandemic potential, which is being used to test vaccine candidates from CEPI-supported developers in Europe and India. The resulting data helped support progress toward human clinical trials.

SUPPORTING A MCGILL-LED TB RESEARCH CONSORTIUM

VIDO supported an international tuberculosis research consortium led by McGill University with collaborators from Penn State, Statens Serum Institut in Denmark, and other Canadian and U.S. institutions. With funding from the Canadian Institutes of Health Research and The Gates Foundation, the project developed cattle models that allow researchers to better understand how TB infection develops and how future vaccines or treatments could be tested.

Published in one of the leading scientific journals – *Proceedings of the National Academy of Sciences*, this work highlights VIDO's role as a national science facility that supports partner-led research through specialized animal research expertise and infrastructure. By making these capabilities available to collaborators, VIDO helps strengthen TB research for both human and animal health.

WORLD LEADING CONTAINMENT FACILITIES AND CAPACITY

INFRASTRUCTURE BUILT FOR READINESS, RESPONSE AND IMPACT



VIDO's containment facilities help ensure that Canada and the world are prepared for infectious disease threats that can affect people, animals, agriculture, food security, and sovereignty. With advanced containment laboratories, specialized animal facilities, and vaccine manufacturing capacity, VIDO supports the full research and development continuum, from studying pathogens to testing vaccines and advancing potential solutions.

These facilities are part of Canada's broader research infrastructure and are now considered a national asset. They enable research on high-consequence pathogens and support the development of vaccines, therapeutics, and other medical countermeasures against biological threats to both humans and animals.

To strengthen readiness, VIDO continues to enhance three key areas: vaccine manufacturing, elevated containment, and new animal housing.

DOMESTIC VACCINE MANUFACTURING CAPACITY WHEN IT MATTERS

VIDO's Vaccine Development Centre is a GMP-compliant biomanufacturing facility capable of operating at containment level 3. It supports the development and scale-up of vaccines for human and animal health, strengthening Canada's domestic medical countermeasure capacity, supply-chain resilience and readiness to respond to health emergencies and biological threats.

The facility can produce all standard vaccine platforms and is exploring other medical countermeasures, including monoclonal antibodies, to diversify its capabilities. It has already supported projects involving vaccines for fish, cattle and pigs, as well as a broadly protective coronavirus vaccine for people. This breadth reflects VIDO's role as a national asset supporting health security and preparedness across species and sectors.

ELEVATED CONTAINMENT CAPABILITIES FOR HIGH-CONSEQUENCE PATHOGENS

VIDO continues to advance toward establishing containment level 4 capacity for research on high-consequence pathogens. Once complete, VIDO will be the only non-government CL4 facility in Canada, expanding the country's ability to safely study the world's highest-risk biological threats.

This new capacity will enable VIDO to work across the full spectrum of human and animal pathogens, including emerging and previously unknown threats. Combined with VIDO's existing research, animal model and vaccine manufacturing capabilities, it will strengthen Canada's ability to develop, test and advance medical countermeasures while supporting pandemic preparedness, biodefence and national health security.

EXPANDED CL2 ANIMAL HOUSING CAPACITY

VIDO is nearing completion of a new containment level 2 animal housing facility that will enhance research capacity, ensuring that VIDO continues to play a key role in supporting human and animal health. This new facility will be over six times larger than the original facility and have the capability of housing a broader range of animals, including bats and insects, which are often linked to new outbreaks. It will also provide expanded livestock capacity. The new facility will also offer increased enrichment opportunities for animals to enhance their welfare and support ethical standards through the 3Rs of animal research (replacement, reduction, refinement).



Strategic Global **PARTNERSHIPS**



VIDO continued to strengthen relationships with a variety of national and international partners including those from academia, industry, and government, supporting its role as a trusted partner in infectious disease preparedness. Targeted partnership activities helped expand awareness of VIDO's end-to-end research and development/manufacturing capabilities. This includes new business opportunities such as the completion of its first external manufacturing contract for a European partner, and new strategic partnerships as outlined below.

Strategic partnerships continued to grow, including formal renewal of VIDO's long-standing collaboration with the International Vaccine Institute (IVI), based in South Korea, through a memorandum of understanding focused on post-pandemic global health. The signing was witnessed by the Honorable Warren Kaeding, SK Minister Responsible for Innovation. VIDO also expanded its role in international preparedness networks, including designation by the United Nations as a Qualified Laboratory to support the Secretary-General's Mechanism for investigating biological

threats, and increased participation in NATO initiatives, including the inaugural biotechnology meeting in Brussels.

VIDO contributed to national policy and sector discussions through engagement with the Public Health Agency of Canada, BIOTEC Canada's Emerging Companies Advisory Board, and Council of Canadian Academies initiatives on research security and open science. VIDO staff also provided technical and operational input through PHAC's Biocontainment Engineering Science Working Group and stakeholder engagement on the Biosecurity Addendum to the Canadian Biosafety Standard.

Together, these partnerships and leadership roles enhance VIDO's ability to significantly contribute across disciplines and sectors, expand access to emerging technologies, and contribute to national and global responses to infectious disease and biodefence challenges.

FUNDING

VIDO's impact is made possible through the continued investment of partners who recognize the importance of pandemic preparedness, infectious disease research, and specialized research infrastructure.

This investment comes from a broad network that includes federal funding from the Canada Foundation for Innovation (CFI), ISED and PrairiesCan, provincial funding from Innovation Saskatchewan and the Ministry of Agriculture as well as the City of Saskatoon, the livestock sector, foundations, human and animal health companies, research partners, and philanthropists. Together, these contributors help sustain the people, facilities, partnerships, and training environments needed to respond to emerging health challenges.


As VIDO continues to grow as Canada's Centre for Pandemic Research, reliable operating funding remains essential to maintaining its specialized capacity. Continued investment strengthens Canada's research and innovation ecosystem by enabling scientific collaboration, training the next generation of researchers, and supporting timely responses to new infectious disease threats.

VIDO has recently been designated by the Government of Canada as a Major Research Facility, recognizing its importance to Canada's research

landscape as a National Asset. While federal funding for the Major Research Facilities program remains under consideration it is essential to the long-term strategic operations of the Major Research Facilities and would help underpin VIDO's national role and long-term readiness.

In 2025-26, VIDO's overall revenue reached \$75.3M, an increase of 15% compared to the previous fiscal year. This growth was driven by new research grants, contract research activity, and continued investments in VIDO's development as Canada's Centre for Pandemic Research. Total expenses increased by 14% to \$71.9 million, primarily reflecting the timing and scale of expenditures associated with ongoing infrastructure projects. VIDO is grateful to all contributors for their role in strengthening research, expanding national capacity, supporting trainees and collaborators, and advancing preparedness in Canada and around the world. We are especially pleased to recognize our philanthropic Friends of VIDO donors on pages 22–23, along with our other contributors on page 24.

OPERATIONAL AND RESEARCH FUNDING



- 71% Federal
- 14% Non-government
- 10% Provincial
- 3% User fees
- 1% Donations
- 1% Other funding

USE OF FUNDS



- 44% Investment in infrastructure
- 24% Salaries and benefits
- 23% Materials and supplies
- 3% Capital assets
- 3% Maintenance
- 2% Utilities
- 1% Travel and recruiting

Friends of VIDO

The Friends of VIDO philanthropic campaign is driven by the generosity of individuals and organizations who believe in VIDO's mission to protect humanity.

Philanthropic support provides VIDO the opportunity to strengthen areas that are essential to long-term preparedness. Contributions help support specialized equipment, infrastructure, training, and the recruitment of leading scientific talent through research chairs and fellowships.

By becoming a Friend of VIDO, donors help shape the future of infectious disease research and ensure VIDO is ready to respond to the health challenges of tomorrow. Learn more or donate at vido.org/donate.

DONOR ROLL

The following list recognizes the donations committed or received
May 1, 2025 - April 30, 2026

GIFTS OF \$25,000 TO \$99,000

Matthew and Kimberley Coutts
Ron Olson

GIFTS OF \$5,000 TO \$24,999

Bob & Kathy Burnyeat
Hertha Pfeifer
Lloyd & Shirley Widenmaier
Lynne Samson
Robin Chapman & Ian Judd-Henrey
Warren & Doreen Clubb

GIFTS OF UP TO \$4,999

Andrew & Breanne
Couperthwaite

Andrew Rauert

Bill Black

Bill Szautner

Blair Bley

Bob & Claire Hart

Brian & Barbara Crow

Brodie Garratt

Carol Summer

Chris Benz

Dailene & Shannon Kells

Damian Zimmer

Dennis & Toni Beerling

Dr. Barb Eatock

Elizabeth Hampson

Evan Ingram

Evan Michel

Fernando Gaspar

Gary & Karin Corbin

Gary Beck

Gord Meuller

Gord Stewart & Maria Styacko

Grant Cheston

Ivy McGrath

James & Bonnie Wilson

Janet Grest

Janice Crawford

Jan-Mark & Sharon Gustafson

Jeff & Alison Michel

Johnathan Michel

Kenneth Howland &

Marcia Clark

Kirk Muyres

Lenore Fletcher

Leona Schemenauer

Leroy Feeds

Linda Charlton

Linnae Treleaven

Lionel Stehr

Lizee Gauthier

Lori Gauthier

Lyle Kuntz

Mark Beck

Martin & Cheryl Erlandson

Michelle Fagnou

Nancy Kot

Neil & Fay Gabrielson

Paul Radigan

Peter Kneeland

Robin Benz

Rory McAlpine

Roxanne & Colin McHattie

Sandra Arnett

Shaina Ilg

St. Gregor Co-Operative
Community Club

Susan Leitch

Terry Bedard

The Hon. Lynne M. Yelich P.C

Thomas Lessmeister

Travis Tasa

Twyla Salmond

Tyler Hogemann

Vern Kiefer

Wade Beck

Wes Crone

2025-26 CONTRIBUTORS

Alberta Beef Producers
 Alberta Conservation Association
 Alberta Milk
 Alberta Pork
 Beef Cattle Research Council
 Boston Children's Hospital
 Canada Biomedical Research
 Fund and Biosciences Research
 Infrastructure Fund
 Canada Foundation for
 Innovation (CFI)
 Canadian Cattle Association
 Canadian Food Inspection Agency
 Canadian Institutes of Health
 Research (CIHR)
 Canadian Poultry Research Council
 Coalition for Epidemic
 Preparedness Innovations
 Congressionally Directed Medical
 Research Programs (CDMRP)
 Department of War (US)
 Egg Farmers of Canada
 Emory University
 The Gates Foundation
 Government of Saskatchewan
 Grand Challenge Canada
 Guangzhou Yuanbo Medical
 Tech Co.
 Harvard University

Health Emergency
 Readiness Canada
 Innovation Saskatchewan
 Institut Jules Bordet
 International Development
 Research Centre (IDRC)
 Kamloops Stockmen's Association
 KreaMedica
 Laval University
 McGill University
 McMaster University
 Ministry of Agriculture –
 Agriculture Development
 Fund (ADF)
 Ministry of Environment
 Mitacs
 Modulant Bio Science
 National Institute of Allergy and
 Infectious Diseases (NIAID)
 National Institutes of Health (NIH)
 Natural Sciences and Engineering
 Research Council (NSERC)
 New Frontiers in Research Fund
 Parks Canada
 Pennsylvania State University
 Pirbright Institute
 Results Driven Agriculture
 Research (RDAR)
 Roslin Institute

Saskatchewan Cattle Association
 Saskatchewan Health Research
 Foundation (SHRF)
 Saskatchewan Pork
 Development Board
 Seacure AG
 Social Sciences and Humanities
 Research Council (SSHRC)
 State University of New York
 Swine Health Information
 Center (USA)
 Swine Innovation Porc
 True North Bioscience
 University of Alberta
 University of British Columbia
 University of Chicago
 University of Guelph
 University of Manitoba
 University of Montana
 University of Texas
 University of Toronto
 Uvax Bio LLC
 Vaccine Formulation Institute
 Western College of Veterinary
 Medicine (WCVI)
 World Health Organization (WHO)
 World Organization of
 Animal Health (WOAH)





VACCINE AND INFECTIOUS DISEASE ORGANIZATION

University of Saskatchewan 120 Veterinary Road

Saskatoon, SK S7N 5E3

+1-306-966-7465

info@vido.org